Resveratrol protects leukemic cells against cytotoxicity induced by proteasome inhibitors via induction of FOXO1 and p27Kip1

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Niu, Xiao Fang ^a,b   Liu, Bao Qin ^a,b   Du, Zhen Xian ^a   Gao, Yan Yan ^a   Li, Chao ^a   Li, Ning ^a   Guan, Yifu ^a   Wang, Hua Qin ^a,b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CYCLIN DEPENDENT KINASE INHIBITOR 1B; RESVERATROL; TRANSCRIPTION FACTOR FKHR; CYTOTOXIN; ENZYME INHIBITOR; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; PROTEASOME; STILBENE DERIVATIVE;

APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CELL PROTECTION; CELL VIABILITY; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG MECHANISM; ENZYME INDUCTION; FLOW CYTOMETRY; LEUKEMIA CELL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INDUCTION; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING; CELL STRAIN K 562; CELL STRAIN U937; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; LEUKEMIA; PATHOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

APOPTOSIS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE INHIBITOR P27; CYTOPROTECTION; CYTOTOXINS; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; K562 CELLS; LEUKEMIA; PROTEASOME ENDOPEPTIDASE COMPLEX; STILBENES; U937 CELLS;

EID: 79952696809     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-99     Document Type: Article

References (54)

1. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998, 67:425-479. 10.1146/annurev.biochem.67.1.425, 9759494.
2. Baumeister W, Walz J, Zuhl F, Seemuller E. The proteasome: paradigm of a self-compartmentalizing protease. Cell 1998, 92(3):367-380. 10.1016/S0092-8674(00)80929-0, 9476896.
3. Jagani Z, Song K, Kutok JL, Dewar MR, Melet A, Santos T, Grassian A, Ghaffari S, Wu C, Yeckes-Rodin H, et al. Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors. Cancer Res 2009, 69(16):6546-6555. 10.1158/0008-5472.CAN-09-0605, 2763358, 19654305.
4. Deleu S, Lemaire M, Arts J, Menu E, Van Valckenborgh E, Vande Broek I, De Raeve H, Coulton L, Van Camp B, Croucher P, et al. Bortezomib alone or in combination with the histone deacetylase inhibitor JNJ-26481585: effect on myeloma bone disease in the 5T2 MM murine model of myeloma. Cancer Res 2009, 69(13):5307-5311. 10.1158/0008-5472.CAN-08-4472, 19531653.
5. Fulda S, Debatin KM. Sensitization for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by the chemopreventive agent resveratrol. Cancer Res 2004, 64(1):337-346. 10.1158/0008-5472.CAN-03-1656, 14729643.
6. Gill C, Walsh SE, Morrissey C, Fitzpatrick JM, Watson RW. Resveratrol sensitizes androgen independent prostate cancer cells to death-receptor mediated apoptosis through multiple mechanisms. Prostate 2007, 67(15):1641-1653. 10.1002/pros.20653, 17823925.
7. Fulda S, Debatin KM. Sensitization for anticancer drug-induced apoptosis by the chemopreventive agent resveratrol. Oncogene 2004, 23(40):6702-6711. 10.1038/sj.onc.1207630, 15273734.
8. Zhou R, Fukui M, Choi HJ, Zhu BT. Induction of a reversible, non-cytotoxic S-phase delay by resveratrol: implications for a mechanism of lifespan prolongation and cancer protection. Br J Pharmacol 2009, 158(2):462-474. 10.1111/j.1476-5381.2009.00268.x, 2757685, 19563536.
9. Kubota T, Uemura Y, Kobayashi M, Taguchi H. Combined effects of resveratrol and paclitaxel on lung cancer cells. Anticancer Res 2003, 23(5A):4039-4046.
10. Jazirehi AR, Bonavida B. Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2004, 3(1):71-84. 10.4161/cbt.3.1.683, 14749477.
11. Ivanov VN, Partridge MA, Johnson GE, Huang SX, Zhou H, Hei TK. Resveratrol sensitizes melanomas to TRAIL through modulation of antiapoptotic gene expression. Exp Cell Res 2008, 314(5):1163-1176. 10.1016/j.yexcr.2007.12.012, 18222423.
12. Scarlatti F, Sala G, Ricci C, Maioli C, Milani F, Minella M, Botturi M, Ghidoni R. Resveratrol sensitization of DU145 prostate cancer cells to ionizing radiation is associated to ceramide increase. Cancer Lett 2007, 253(1):124-130. 10.1016/j.canlet.2007.01.014, 17321671.
13. Bhardwaj A, Sethi G, Vadhan-Raj S, Bueso-Ramos C, Takada Y, Gaur U, Nair AS, Shishodia S, Aggarwal BB. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-kappaB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007, 109(6):2293-2302. 10.1182/blood-2006-02-003988, 17164350.
14. Drexler HC. Activation of the cell death program by inhibition of proteasome function. Proc Natl Acad Sci USA 1997, 94(3):855-860. 10.1073/pnas.94.3.855, 19603, 9023346.
15. Drexler HC, Risau W, Konerding MA. Inhibition of proteasome function induces programmed cell death in proliferating endothelial cells. Faseb J 2000, 14(1):65-77.
16. Hirano M, Hirano K, Nishimura J, Kanaide H. Transcriptional up-regulation of p27(Kip1) during contact-induced growth arrest in vascular endothelial cells. Exp Cell Res 2001, 271(2):356-367. 10.1006/excr.2001.5384, 11716548.
17. Polyak K, Kato JY, Solomon MJ, Sherr CJ, Massague J, Roberts JM, Koff A. p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest. Genes Dev 1994, 8(1):9-22. 10.1101/gad.8.1.9, 8288131.
18. Drexler HC, Pebler S. Inducible p27(Kip1) expression inhibits proliferation of K562 cells and protects against apoptosis induction by proteasome inhibitors. Cell Death Differ 2003, 10(3):290-301. 10.1038/sj.cdd.4401159, 12700629.
19. Lynch RL, Konicek BW, McNulty AM, Hanna KR, Lewis JE, Neubauer BL, Graff JR. The progression of LNCaP human prostate cancer cells to androgen independence involves decreased FOXO3a expression and reduced p27KIP1 promoter transactivation. Mol Cancer Res 2005, 3(3):163-169. 10.1158/1541-7786.MCR-04-0163, 15798096.
20. Tang ED, Nunez G, Barr FG, Guan KL. Negative regulation of the forkhead transcription factor FKHR by Akt. J Biol Chem 1999, 274(24):16741-16746. 10.1074/jbc.274.24.16741, 10358014.
21. Liu BQ, Gao YY, Niu XF, Xie JS, Meng X, Guan Y, Wang HQ. Implication of unfolded protein response in resveratrol-induced inhibition of K562 cell proliferation. Biochem Biophys Res Commun 2010, 391(1):778-782. 10.1016/j.bbrc.2009.11.137, 19944671.
22. Yin D, Zhou H, Kumagai T, Liu G, Ong JM, Black KL, Koeffler HP. Proteasome inhibitor PS-341 causes cell growth arrest and apoptosis in human glioblastoma multiforme (GBM). Oncogene 2005, 24(3):344-354. 10.1038/sj.onc.1208225, 15531918.
23. Bazzaro M, Lee MK, Zoso A, Stirling WL, Santillan A, Shih Ie M, Roden RB. Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis. Cancer Res 2006, 66(7):3754-3763. 10.1158/0008-5472.CAN-05-2321, 16585202.
24. Soligo D, Servida F, Delia D, Fontanella E, Lamorte G, Caneva L, Fumiatti R, Lambertenghi Deliliers G. The apoptogenic response of human myeloid leukaemia cell lines and of normal and malignant haematopoietic progenitor cells to the proteasome inhibitor PSI. Br J Haematol 2001, 113(1):126-135. 10.1046/j.1365-2141.2001.02683.x, 11328292.
25. Orlowski RZ, Eswara JR, Lafond-Walker A, Grever MR, Orlowski M, Dang CV. Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a proteasome inhibitor. Cancer Res 1998, 58(19):4342-4348.
26. Nasr R, El-Sabban ME, Karam JA, Dbaibo G, Kfoury Y, Arnulf B, Lepelletier Y, Bex F, de The H, Hermine O, et al. Efficacy and mechanism of action of the proteasome inhibitor PS-341 in T-cell lymphomas and HTLV-I associated adult T-cell leukemia/lymphoma. Oncogene 2005, 24(3):419-430. 10.1038/sj.onc.1208212, 15543232.
27. Agrawal D, Hauser P, McPherson F, Dong F, Garcia A, Pledger WJ. Repression of p27kip1 synthesis by platelet-derived growth factor in BALB/c 3T3 cells. Mol Cell Biol 1996, 16(8):4327-4336. 231431, 8754833.
28. Srivastava RK, Unterman TG, Shankar S. FOXO transcription factors and VEGF neutralizing antibody enhance antiangiogenic effects of resveratrol. Mol Cell Biochem 2010, 337(1-2):201-212. 10.1007/s11010-009-0300-5, 20012470.
29. Ganjam GK, Dimova EY, Unterman TG, Kietzmann T. FoxO1 and HNF-4 are involved in regulation of hepatic glucokinase gene expression by resveratrol. J Biol Chem 2009, 284(45):30783-30797. 10.1074/jbc.M109.045260, 2781477, 19740748.
30. Medema RH, Kops GJ, Bos JL, Burgering BM. AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 2000, 404(6779):782-787. 10.1038/35008115, 10783894.
31. Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW, Koenderman L, et al. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol 2000, 20(24):9138-9148. 10.1128/MCB.20.24.9138-9148.2000, 102172, 11094066.
32. Nakamura N, Ramaswamy S, Vazquez F, Signoretti S, Loda M, Sellers WR. Forkhead transcription factors are critical effectors of cell death and cell cycle arrest downstream of PTEN. Mol Cell Biol 2000, 20(23):8969-8982. 10.1128/MCB.20.23.8969-8982.2000, 86551, 11073996.
33. Hu Z, Pan XF, Wu FQ, Ma LY, Liu DP, Liu Y, Feng TT, Meng FY, Liu XL, Jiang QL, et al. Synergy between proteasome inhibitors and imatinib mesylate in chronic myeloid leukemia. PLoS One 2009, 4(7):e6257. 10.1371/journal.pone.0006257, 2705802, 19606213.
34. Shah JJ, Orlowski RZ. Proteasome inhibitors in the treatment of multiple myeloma. Leukemia 2009, 23(11):1964-1979. 10.1038/leu.2009.173, 19741722.
35. Paoluzzi L, Scotto L, Marchi E, Seshan VE, O'Connor OA. The anti-histaminic cyproheptadine synergizes the antineoplastic activity of bortezomib in mantle cell lymphoma through its effects as a histone deacetylase inhibitor. Br J Haematol 2009, 146(6):656-659. 10.1111/j.1365-2141.2009.07797.x, 19604235.
36. Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ, et al. The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 2009, 23(8):1507-1514. 10.1038/leu.2009.41, 19282831.
37. Drexler HC. Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors. PLoS One 2009, 4(1):e4161. 10.1371/journal.pone.0004161, 2613525, 19129918.
38. Touzet O, Philips A. Resveratrol protects against protease inhibitor-induced reactive oxygen species production, reticulum stress and lipid raft perturbation. Aids 2010, 24(10):1437-1447. 10.1097/QAD.0b013e32833a6114, 20539089.
39. Chakraborty PK, Mustafi SB, Ganguly S, Chatterjee M, Raha S. Resveratrol induces apoptosis in K562 (chronic myelogenous leukemia) cells by targeting a key survival protein, heat shock protein 70. Cancer Sci 2008, 99(6):1109-1116. 10.1111/j.1349-7006.2008.00809.x, 18429957.
40. Goswami SK, Das DK. Resveratrol and chemoprevention. Cancer Lett 2009, 284(1):1-6. 10.1016/j.canlet.2009.01.041, 19261378.
41. Jannin B, Menzel M, Berlot JP, Delmas D, Lancon A, Latruffe N. Transport of resveratrol, a cancer chemopreventive agent, to cellular targets: plasmatic protein binding and cell uptake. Biochem Pharmacol 2004, 68(6):1113-1118. 10.1016/j.bcp.2004.04.028, 15313407.
42. Asensi M, Medina I, Ortega A, Carretero J, Bano MC, Obrador E, Estrela JM. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 2002, 33(3):387-398. 10.1016/S0891-5849(02)00911-5, 12126761.
43. Walle T, Hsieh F, DeLegge MH, Oatis JE, Walle UK. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004, 32(12):1377-1382. 10.1124/dmd.104.000885, 15333514.
44. Li L, Zhang G, Zhang Y, Tan J, Huang H, Huang B, Lu J. Sodium butyrate-induced upregulation of p18(INK4C) gene affects K562 cell G (0)/G (1) arrest and differentiation. Mol Cell Biochem 2008, 319(1-2):9-15. 10.1007/s11010-008-9870-x, 18642058.
45. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998, 5(12):1062-1075. 10.1038/sj.cdd.4400436, 9894613.
46. Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH, Seth P. Promoting apoptosis: a novel activity associated with the cyclin-dependent kinase inhibitor p27. Cancer Res 1997, 57(24):5441-5445.
47. Wang X, Gorospe M, Huang Y, Holbrook NJ. p27Kip1 overexpression causes apoptotic death of mammalian cells. Oncogene 1997, 15(24):2991-2997. 10.1038/sj.onc.1201450, 9416843.
48. Kudo Y, Takata T, Ogawa I, Kaneda T, Sato S, Takekoshi T, Zhao M, Miyauchi M, Nikai H. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 2000, 6(3):916-923.
49. Sun J, Nam S, Lee CS, Li B, Coppola D, Hamilton AD, Dou QP, Sebti SM. CEP1612, a dipeptidyl proteasome inhibitor, induces p21WAF1 and p27KIP1 expression and apoptosis and inhibits the growth of the human lung adenocarcinoma A-549 in nude mice. Cancer Res 2001, 61(4):1280-1284.
50. Eymin B, Haugg M, Droin N, Sordet O, Dimanche-Boitrel MT, Solary E. p27Kip1 induces drug resistance by preventing apoptosis upstream of cytochrome c release and procaspase-3 activation in leukemic cells. Oncogene 1999, 18(7):1411-1418. 10.1038/sj.onc.1202437, 10050878.
51. Dimanche-Boitrel MT, Micheau O, France D, Hammann A, Duchamp O, Genne P, Solary E. P27KiP1 overexpression inhibits the growth and doxorubicin sensitivity of HT29 human colon cancer cells in vivo. Anticancer Res 2000, 20(2A):849-852.
52. Masuda A, Osada H, Yatabe Y, Kozaki K, Tatematsu Y, Takahashi T, Hida T, Takahashi T, Takahashi T. Protective function of p27(KIP1) against apoptosis in small cell lung cancer cells in unfavorable microenvironments. Am J Pathol 2001, 158(1):87-96. 10.1016/S0002-9440(10)63947-8, 1850277, 11141482.
53. Denicourt C, Dowdy SF. Cip/Kip proteins: more than just CDKs inhibitors. Genes Dev 2004, 18(8):851-855. 10.1101/gad.1205304, 15107401.
54. Taniguchi T, Endo H, Chikatsu N, Uchimaru K, Asano S, Fujita T, Nakahata T, Motokura T. Expression of p21(Cip1/Waf1/Sdi1) and p27(Kip1) cyclin-dependent kinase inhibitors during human hematopoiesis. Blood 1999, 93(12):4167-4178.